Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease.
about
Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in miceElevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophagesCompartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains.ABCD of the phosphodiesterase family: interaction and differential activity in COPDRare Variants Association Analysis in Large-Scale Sequencing Studies at the Single Locus LevelChronic obstructive pulmonary disease, inflammation and PDE4 inhibitors.Small-molecule inhibitors of PDE-IV and -VII in the treatment of respiratory diseases and chronic inflammation.Evaluation of PDE4 inhibition for COPD.Treating COPD with PDE 4 inhibitors.G protein-coupled receptor connectivity to NF-kappaB in inflammation and cancer.Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.Is there a role for antiinflammatory treatment in COPD?Clinical and molecular genetics of the phosphodiesterases (PDEs).Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseaseDual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs.
P2860
Q24651941-8AB57705-5A5D-4A07-8C6C-07FCB62849A6Q28487329-4169D69E-7CE7-48CE-BE27-E0486DC5B725Q33564601-2D552A10-4126-47A8-A393-8AD6ACB66BBFQ33721181-D6529209-5011-49B3-8008-14F2BA6BBB15Q34961511-D9D4FB63-19F7-492E-A9B8-3169ABD65264Q36063830-F8785A25-9674-47B6-A2C9-C6681F768C6FQ36554689-E3ABCDDC-E280-4B4E-8949-837D28A9E351Q36964706-33EA1493-D6CA-4D24-8D28-D75A45E754D8Q37017332-5272EE6D-2400-4CFF-A483-8CF5E997874EQ37082594-6048EB6E-BD66-436B-9E6C-BAA13E3C7263Q37293340-1C686D39-C926-45CF-A723-B1C0FEE34F30Q37332621-C35383BE-F3E0-4F7E-B6C4-E2D58E3AF604Q37622935-DD550F34-EED7-468A-B0D1-DF06D759D93BQ37657841-465EC56D-8496-4D82-BBD2-1D64F1AC8CF4Q37828179-0552F1CB-F0A7-44E0-A4E9-9FEB82EAC4EEQ38187182-1EAB8858-07A2-43B0-AA94-D0F01D868A2DQ39322017-DBED4E91-BA94-40F2-816F-6831DEE34C84Q50002026-853CD74C-CB53-45AD-9F2C-48D5465E24B8
P2860
Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Phosphodiesterase-4: selective ...... obstructive pulmonary disease.
@ast
Phosphodiesterase-4: selective ...... obstructive pulmonary disease.
@en
type
label
Phosphodiesterase-4: selective ...... obstructive pulmonary disease.
@ast
Phosphodiesterase-4: selective ...... obstructive pulmonary disease.
@en
prefLabel
Phosphodiesterase-4: selective ...... obstructive pulmonary disease.
@ast
Phosphodiesterase-4: selective ...... obstructive pulmonary disease.
@en
P1476
Phosphodiesterase-4: selective ...... obstructive pulmonary disease.
@en
P2093
Mark A Giembycz
P304
326-33; discussion 340-1
P356
10.1513/PATS.200504-041SR
P577
2005-01-01T00:00:00Z